Journal Image
Current Pharmaceutical Biotechnology
ISSN (Print): 1389-2010
ISSN (Online): 1873-4316
DOI: 10.2174/138920112800784772      Price:  $58

Treating Impaired Cognition in Schizophrenia

Author(s): H. M. Ibrahim and C. A. Tamminga
Pages 1587-1594 (8)
Cognitive impairment is a core feature of schizophrenia that substantially accounts for poor functional outcomes associated with this disease in areas such as work, independent living and social relationships. Until recently, drug development in schizophrenia has focused on developing compounds that mainly target the positive psychotic symptoms of the illness. Although current antipsychotic drugs treat psychosis in schizophrenia rather well, their impact on cognitive dysfunction is minimal. In recent years there has been growing interest in developing novel treatments for cognitive deficits in schizophrenia. In this review we discuss pharmacologic strategies considered most likely to improve cognition. These putative molecular targets include receptors for acetylcholine, dopamine, glutamate, g-aminobutyric acid (GABA), serotonin and histamine. In addition, we propose that not only pharmacological, but also psychological treatments should be considered to enhance cognition in schizophrenia.
Cognition, Acetylcholine, Glutamate, Dopamine, Histamine, Serotonin, GABA, Cognitive remediation, core feature, schizophrenia, social relationships, schizophrenia, psychotic symptoms, pharmacologic strategies
Department of Psychiatry, UT Southwestern Medical Center 5323 Harry Hines Blvd., Dallas, TX 75390- 9086, USA.